| Matthew Porteus | |
| Alma Mater: | Harvard University Stanford University |
| Workplaces: | Stanford University California Institute of Technology Massachusetts Institute of Technology |
| Thesis Title: | Isolation and Characterization of TES-1/DLX-2: A Novel Homeobox Gene Expressed During Mammalian Forebrain Development |
| Thesis Url: | https://searchworks.stanford.edu/view/5635658 |
| Thesis Year: | 1994 |
Matthew Hebden Porteus is Sutardja Chuk Professor of Definitive and Curative Medicine at Stanford University.[1] In 2003, as a postdoctoral fellow in David Baltimore's lab at the California Institute of Technology, Porteus was the first to demonstrate precise gene editing in human cells using chimeric nucleases.[2]
He graduated magna cum laude from Harvard University and completed his MD and PhD at Stanford University.[3] For his post-doctoral work he trained with David Baltimore at MIT and Caltech.[3] He is a scientific founder of CRISPR Therapeutics and an academic founder of Graphite Bio.[4] [5]
He has an h-index of 69 according to Google Scholar.[6]